SAMOA

BURDEN OF CANCER




Premature deaths from NCDs (2016)
307

Cancer as % of NCD premature deaths (2016)

29.1%


Most common cancer cases (2018)




	20.0%	3.1%	21.5%	5.6%	n/a	1.0%
PAFS (population attributable fractions)	Tobacco (2017) ^a	Alcohol (2016) ^a	Infections (2012) ^b	Obesity (2012) ^b	UV (2012)°	Occupational risk (2017) ^a
indecions)	^a PAF, cancer deaths	^b PAF, cancer cases	^c PAF, melanoma cases			

TRENDS

Estimated past and future trends in total cases per year (breast and lung)




Probability of premature death from cancer per year



INVESTMENT CASE (2019)

*Upper middle income









petaty (PECK)** Post petaty Peck Peck Peck Peck	° per 10,000 cancer patients Availability of population-based cancer 2019 PBCR			WORKFORCE			
content beam radiotherapy of external beam radiotherapy of mammographs* 2019 2019 0.0 0 and radiation external beam radiotherapy of mammographs* 2020 29.2 0 for a radiation concologist* 2019 0 of Tardiation on concologist* 2014 144 145 0 of Tardiation on concologist* 2014 146 0 of Tardiation on concologist* 2014 147 0 of Tardiation on concologist* 2014 148 0 of Tardiation on concologist* 2014 149 0 of Tardiation on concologist* 2019 0 of Tardiation cancer centered program 2019 0 operational 2019 0 of Tardiation on concologist* 2019 0 of Tardiation on concologi	egistry (PBCR)**	2013	rbek				
of external beam radiotherapy hototone electron)** 2019 0.0 # of madiation oncologist* 2019 remove the foliation of cologist* 2019 remove the foliation of feet or PET/CT scanners* 2020 0.0 # of muckar medicine physician* 2019 of PET or PET/CT scanners* 2020 0.0 # of muckar medicine physician* 2019 remove the foliation of PET or PET/CT scanners* 2020 0.0 # of medical & pathology lab scientists* 2014 107/1	uality of mortality registration***	2007-2016	No coverage	dedicates significant proportion of their	2019	ne	
and medical physicists* 2019 of mammographs* 2020 29.2 B of nardical physicists* 2014 144 of GT scanners* 2020 29.2 B of surgeons* 2014 144 145 145 2019 of Texanors* 2020 0.0 B of nuclear medicine physician* 2019 of PET of PET/CT scanners* 2020 0.0 B of nuclear medicine physician* 2019 0 PET of PET/CT scanners* 2020 0.0 B of medical & pathology lab scientists* 2014 1077 1077 1077 1077 1077 1077 1077 1	of external beam radiotherapy	2019	0.0		2019	n/a	
of CT scanners* 2020 29.2 # of radiologist* 2019 of Ref radiologist* 2019 of Ref radiologist* 2019 of Ref ro ref ref ro ref ref ro ref	photon,electron) ^a	2013	0.0	# of medical physicist ^a	2019	n/	
of MRI scanners* 2020 0.0 # of nuclear medicine physician* 2019 of PET or PET/CT scanners* 2020 0.0 # of medical & pathology lab scientists* 2014 1077 FORMULATING RESPONSE Integrated NCD plan 2019 operational patients 2019 operational patients 2019 operational patients 2019 operational 2018 1 Pathology services 2019 operational 2018 Pathology services 2019 generally available thieved and chieved anarer management guidelines 2019 Bone marrow transplantation capacity 2019 generally available thieved 2019 Pathology services 20	of mammographs ^a	2020	29.2	# of surgeons ^a	2014	145.	
FORMULATING RESPONSE **To PET/CT scanners** 2019	of CT scanners ^a	2020	29.2	# of radiologist ^a	2019	n/	
regrated NCD plan 2019 operational Early detection programme/ guidelines for acares you cancer wanagement guidelines 2019	f of MRI scanners ^a	2020	0.0	# of nuclear medicine physician ^a	2019	0.	
ntegrated NCD plan 2019 operational 2019 properational patients 2019 perational 2019 operational 2019 operational 2019 operational 2019 operational 2019 operational 2019 operational 2019 and 2019 operational 2019 and 2019 operational 2018 1 Pathology services 2019 generally available ancer management guidelines 2019 Bone marrow transplantation capacity 2019 alliative care included in their operational, 2019 no 2019 penerally available ancer included in their operational, 2019 no 2019 penerally available ancer included in their operational, 2019 no 2019 penerally available programme (surgery, 2019 penerally available program 2015-2017 penerally available program 2015-2017 penerally available program 2019 penerally available program 2015-2017 penerally available program 2019 penerally available program 2015-2017 pener	of PET or PET/CT scanners ^a	2020	0.0	# of medical & pathology lab scientists ^a	2014	1078.	
patients 2019	ORMULATING RESPONSE						
According cancer types) 2019 operational 4 cancers (breast, cervix, colon, childhood) 2019 one and a cancers (breast, cervix, colon, childhood) 2019 pathology services 2019 generally availat ancer management guidelines 2019 no 2019 pallitative care included in their operational, according to the target and NCD plan of treatment services (surgery, additionary, chemotherapy) 2019 1 Availability of opioids* for pain management guidelines 2019 no 2015-2017 reast cancer screening program 2019 no 2019 no 2019 no 2019 no 2016-2017 reast cancer screening program: Starting 2019 no/a Calcobal Initiative for Childhood Cancer PV vaccination programme coverage 2018 n/a 2019 no 2019 locater of the daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 no 2010 Early detection programme/guidelines 2019 no 2019 locater of the daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 no 2010 Early detection programme/guidelines 2019 no 2019 locater of the daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily doses for statistical purposes (\$-000) per million inhobitions per day 2019 locater daily daily doses for statistical purp	ntegrated NCD plan	2019	operational	ntional		-	
chieved 2018 I Pathology services 2019 Bone marrow transplantation capacity 2019 Bone marrow transplantation capacity 2019 alliative care included in their operational, 2019 no Pallicare are availability: 2019 community/home-based care 2019 generally availability of poloids* for pain 2015-2017 reast cancer screening program 2019 no *Defined doily doses for statistical purposes (5-000) per million inhabitants per day reast cancer screening program: Starting 2019 n/a Global Initiative for Childhood Cancer PV vaccination programme coverage 2018 no Early detection programme/guidelines 2019 no Early detection programme/guidelines 2019 no Early detection programme/guidelines 2019 no Annual cancer cases (0-14 years old) arry detection programme/guidelines 2019 no Pallicare are availability: 2019 penerally availation are availability: 2019 generally availation are availability: 2019 penerally availation are availability: 2019 generally availation are availability of policids* for pain 2015-2017 availability o	NCCP (including cancer types)	2019	operational		2019	0 cancer(s	
alliative care included in their operational, tegrated NCD plan of treatment services (surgery, demotherapy) 2019 1 Availability of opioids* for pain management 2015-2017 reast cancer screening program 2019 10 **Oefined doily doses for statistical purposes (5-000) per million inhabitants per day 2019 10 **Oefined doily doses for statistical purposes (5-000) per million inhabitants per day 2019 2019 10 **Oefined doily doses for statistical purposes (5-000) per million inhabitants per day 2019 2019 2019 2019 2019 2019 2019 2019 2019 2019 2019 2020	MPOWER measures fully implemented and inchieved	2018	1	Pathology services		generally availabl	
Annual cancer cases (0-14 years old) Treesing programme method Treesing programme wethod Treesing programme/guidelines Treesin	ancer management guidelines	2019		Bone marrow transplantation capacity	2019		
Availability of opioids* for pain ananagement 2015-2017 mananagement 2019 no *Defined daily doses for statistical purposes (S-DDD) per million inhabitants per day reast cancer screening program: Starting ge, target population GLOBAL INITIATIVES		2019	no	•	2019	generally availabl	
reast cancer screening program: Starting ge, target population 2019 n/a Global Initiative for Childhood Cancer IPV vaccination programme coverage 2019 n/a Annual cancer cases (0-14 years old) 2019 creening programme type 2019 n/a Defined referral system 2019 n/a Annual cancer cases (0-14 years old) 2019 Annual cancer cases (0-14 years old) Creening programme/guidelines 2019 n/a Annual cancer cases (0-14 years old) Annual cancer cases (0-14 years old) Annual cancer cases (0-14 years old) Accute lymphoid leukaemi Hodgkin lymphoma Burkitt lymphoma Burkitt lymphoma Retinoblastoma Wilms tumour	of treatment services (surgery, adiotherapy, chemotherapy)	2019	1		2015-2017		
ge, target population SIGOBAL INITIATIVES SImination of Cervical Cancer IPV vaccination programme coverage 2018 1019 101 1020 1020 1020 103 104 105 105 105 105 105 105 105	east cancer screening program 2019 no			*Defined daily doses for statistical purposes (S-DDD) per million inhabitants per day			
Climination of Cervical Cancer IPV vaccination programme coverage 2018 1/a 2019 1/a 2019 Annual cancer cases (0-14 years old) 2019 2019 2019 Annual cancer cases (0-14 years old) 2019 20		2019	n/a				
PV vaccination programme coverage 2018 n/a Annual cancer cases (0-14 years old) 2020 ervical cancer screening 2019 no Early detection programme/guidelines 2019 creening programme method 2019 n/a Annual cancer cases (0-14 years old) Accute lymphoid leukaemi Hodgkin lymphoma Burkitt lymphoma Burkitt lymphoma CNS, low grade tumours Retinoblastoma Wilms tumour	GLOBAL INITIATIVES						
creening programme type 2019 n/a Defined referral system 2019 Annual cancer cases (0-14 years old) arrly detection programme/guidelines 2019 Annual cancer cases (0-14 years old) Acute lymphoid leukaemi alterined referral system 2019 Acute lymphoma Burkitt lymphoma Burkitt lymphoma Retinoblastoma Wilms tumour	limination of Cervical Cancer			Global Initiative for Childhood Cancer			
creening programme type 2019 n/a Defined referral system 2019 Annual cancer cases (0-14 years old) CNS, low grade tumours Retinoblastoma Wilms tumour	IPV vaccination programme coverage	2018	n/a	Annual cancer cases (0-14 years old)	2020	1	
creening programme method 2019 n/a Annual cancer cases (0-14 years old) arly detection programme/guidelines 2019 no Acute lymphoid leukaemi lefined referral system 2019 CNS, low grade tumours Retinoblastoma Wilms tumour	ervical cancer screening	2019	no	Early detection programme/guidelines	2019		
Annual cancer cases (0-14 years old)	creening programme type	2019	n/a	Defined referral system	2019		
arly detection programme/guidelines 2019 no Acute lymphoid leukaemi Hodgkin lymphoma Burkitt lymphoma CNS, low grade tumours Retinoblastoma Wilms tumour	creening programme method	2019	n/a				
Refined referral system 2019 Burkitt lymphoma CNS, low grade tumours Retinoblastoma Wilms tumour	creening participation rates 2019		n/a	Annual cancer cases (0-14 years old)			
Prefined referral system 2019 Burkitt lymphoma CNS, low grade tumours Retinoblastoma Wilms tumour	Early detection programme/guidelines	2019	no		■ Acute l	ymphoid leukaemia	
T CNS, low grade tumours Retinoblastoma Wilms tumour	Defined referral system	2019				in lymphoma	
Retinoblastoma Wilms tumour					Burkitt lymphoma		
Retinoblastoma Wilms tumour				7	CNS, lo	w grade tumours	
■ Wilms tumour					■ Retino	blastoma	
					■ Wilms	tumour	
					■ Other	childhood cancer	

^{***}The mortality estimates for this country have a high degree of uncertainty because they are not based on any national NCD mortality data